联合肝脏分隔和门静脉结扎二步肝切除治疗肝门部胆管癌的国际多中心研究
该概念验证研究收集2010至2020年8个中心39例接受联合肝脏分隔和门静脉结扎二步肝切除(ALPPS)的肝门部胆管癌患者,分析并发症、生存及预后因素。结果显示1、3、5年生存率分别为92%、69%、55%,淋巴结阴性患者1、3、5年生存率均为86%。结论提示对ALPPS治疗肝门部胆管癌的批判态度需修正,在精选患者中可获良好生存。
要点
- ALPPS治疗肝门部胆管癌在精选患者中可获良好生存。
- 淋巴结阳性或需附加血管切除者生存较差。
- 淋巴结阴性患者1、3、5年生存率均为86%。
核心结论
- 对ALPPS治疗肝门部胆管癌的批判态度需修正,精选患者可获与既定手术策略相当的生存。
研究设计与样本
- 概念验证研究,收集2010至2020年8个中心39例接受ALPPS的肝门部胆管癌患者。
主要发现
- 术前未来肝残体积中位数323 mL(155-460 mL),未来肝残体积增加中位数58.7%(8.9%-264.5%),两阶段间隔中位数13天(6-60天)。
- 第一阶段后胆漏2例(7.7%),第二阶段后胆漏4例(15%)。
- 第一阶段后6例(23%)和第二阶段后6例(23%)发生3级或以上并发症。
- 第二阶段后90天内死亡2例(7.7%)。
- 1、3、5年生存率分别为92%、69%、55%;淋巴结阴性患者1、3、5年生存率均为86%。
临床怎么用
- 在精选的肝门部胆管癌患者中可考虑ALPPS,需关注淋巴结状态和血管切除对预后的影响。
局限性
- 样本量小(39例),为概念验证研究,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy for perihilar cholangiocarcinoma has been considered to be contraindicated due to the initial poor results. Given the recent reports of improved outcomes, we aimed to collect the recent experiences of different centers performing associating liver partition and portal vein ligation for staged hepatectomy for perihilar cholangiocarcinoma to analyze factors related to improved outcomes. METHODS: This proof-of-concept study collected contemporary cases of associating liver partition and portal vein ligation for staged hepatectomy for perihilar cholangiocarcinoma and analyzed for morbidity, short and long-term survival, and factors associated with outcomes. RESULTS: In total, 39 patients from 8 centers underwent associating liver partition and portal vein ligation for staged hepatectomy for perihilar cholangiocarcinoma from 2010 to 2020. The median preoperative future liver remnant volume was 323 mL (155-460 mL). The median future liver remnant increase was 58.7% (8.9% -264.5%) with a median interstage interval of 13 days (6-60 days). Post-stage 1 and post-stage 2 biliary leaks occurred in 2 (7.7%) and 4 (15%) patients. Six patients (23%) after stage 1 and 6 (23%) after stage 2 experienced grade 3 or higher complications. Two patients (7.7%) died within 90 days after stage 2. The 1-, 3-, and 5-year survival was 92%, 69%, and 55%, respectively. A subgroup analysis revealed poor survival for patients undergoing additional vascular resection and lymph node positivity. Lymph node-negative patients showed excellent survival demonstrated by 1-, 3-, and 5-year survival of 86%, 86%, and 86%. CONCLUSION: This study highlights that the critical attitude toward associating liver partition and portal vein ligation for staged hepatectomy for perihilar cholangiocarcinoma needs to be revised. In selected patients with perihilar cholangiocarcinoma, associating liver partition and portal vein ligation for staged hepatectomy can achieve favorable survival that compares to the outcome of established surgical treatment strategies reported in benchmark studies for perihilar cholangiocarcinoma including 1-stage hepatectomy and liver transplantation.
引用
- Balci D, Nadalin S, Mehrabi A, et al. Revival of associating liver partition and portal vein ligation for staged hepatectomy for perihilar cholangiocarcinoma: An international multicenter study with promising outcomes. Surgery. 2023. PMID: 36959071. doi:10.1016/j.surg.2023.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。